Radiopharmaceutical company Lantheus Holdings (NASDAQ:LNTH) fell short of the market’s revenue expectations in Q1 CY2025, with sales flat year on year at $372.8 million. The company’s full ...

Lantheus Holdings will sell its single photon emission computed tomography, or Spect, business to Illuminated Holdings. The Bedford, Mass., company said Tuesday it will receive an upfront cash ...

BEDFORD, Mass. - Lantheus Holdings, Inc. (NASDAQ: LNTH), a leading company in the radiopharmaceutical field with a market capitalization of $7.2 billion and impressive 18% revenue growth over the ...

Radiopharmaceutical company Lantheus Holdings (NASDAQ:LNTH) will be announcing earnings results tomorrow before market open. Here’s what you need to know. Lantheus beat analysts’ revenue ...

BEDFORD, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to ...

Lantheus Holdings, Inc. (NASDAQ:LNTH – Free Report) – Equities research analysts at Leerink Partnrs issued their Q2 2025 EPS estimates for shares of Lantheus in a research note issued to ...

The firm has a market cap of $5.66 billion, a P/E ratio of 13.54 and a beta of 0.44. Lantheus has a 52-week low of $56.06 and a 52-week high of $126.89. The business’s 50-day moving average ...

Lantheus, a Massachusetts-based developer of radiopharmaceuticals, has agreed to acquire the radiopharma contract development and manufacturing organization (CDMO) Evergreen Theragnostics.

Well before market open that morning, Lantheus announced that it has signed a definitive agreement to acquire clinical-stage peer Evergreen Theragnostics. For its new asset, Lantheus will make an ...

Lantheus will acquire Evergreen Theragnostics for $250 million upfront, plus up to $752.5 million in milestone payments, closing in H2 2025. The Life Molecular Imaging acquisition adds Neuraceq to ...

On a quest to carve out a spot as one of the nuclear medicine greats, Massachusetts-based radiopharmaceutical specialist Lantheus is placing some serious cash on the dealmaking table. In a ...